CAS: 2095432-71-4

GSK269962A HCl is a potent and selective inhibitor of Rho-associated coiled-coil containing protein kinase (ROCK), which is derived from synthetic chemical sources. This inhibitor functions by targeting the ATP-binding site of ROCK I and ROCK II isoforms, thereby blocking their kinase activity. The mode of action involves interfering with the phosphorylation of downstream substrates that are crucial for cytoskeletal dynamics. GSK269962A HCl is widely used in scientific research to elucidate the roles of ROCK signaling pathways in various cellular processes, including smooth muscle contraction, cell motility, and proliferation. It is invaluable in exploring the therapeutic potential of ROCK inhibition in conditions like hypertension, cancer metastasis, and neurodegenerative diseases. By providing insights into the mechanistic pathways, this inhibitor aids in the understanding of ROCK as a therapeutic target and paves the way for the development of drugs tailored for specific pathologies associated with ROCK dysregulation. Its application in preclinical research contributes significantly to unraveling the complexities of cell signaling and disease mechanisms.

GSK269962A hydrochloride (GSK 269962 hydrochloride) is a ROCK inhibitor with anti-inflammatory and vasodilatory effects and inhibits ROCK1 and ROCK2.